Clinical Trial Detail

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

NCT ID	NCT03631706
Title	M7824 Versus Pembrolizumab as a First-line (1L) Treatment in Participants With Programmed Death-ligand 1 (PD-L1) Expressing Advanced Non-small Cell Lung Cancer (NSCLC)
Recruitment	Completed
Gender	both
Phase	Phase II
Variant Requirements	Yes
Sponsors	EMD Serono Research & Development Institute, Inc.
Indications	lung non-small cell carcinoma
Therapies	Bintrafusp alfa Pembrolizumab
Age Groups:	adult \| senior
Covered Countries	USA \| TUR \| NLD \| ITA \| GRC \| FRA \| ESP \| DEU \| CAN \| BRA \| BEL \| ARG